Tag: Andrew Gwynne

The below Parliamentary question was asked by Andrew Gwynne on 2016-10-17.

To ask Mr Chancellor of the Exchequer, if he will extend the matching requirement for the Gift Aid Small Donations Scheme.

Jane Ellison

The Small Charitable Donations and Childcare Payments Bill relaxes the eligibility criteria for the Gift Aid Small Donation Scheme. These changes will ensure that the Scheme operates effectively and flexibly for a greater number of charities and a greater number of donations.

The Government has no plans to extend the Gift Aid matching requirement.

The below Parliamentary question was asked by Andrew Gwynne on 2015-10-28.

To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 11110, how much the NHS spent on cancer services in each year since 2012-13; and what the year-on-year change in that amount was in real terms.

Jane Ellison

Overall National Health Service expenditure on cancer services is not available for 2013-14 or 2014-15. NHS England has published clinical commissioning group (CCG) level expenditure on cancer for 2013-14, which was estimated to be £2.8 billion. CCGs are currently in the process of preparing estimates of expenditure for cancer services in 2014-15.

CCG expenditure is a proportion of overall NHS expenditure, as NHS England commissions some cancer services directly. NHS England is currently reviewing the data on direct commissioning expenditure and plans to publish this when finalised.

The below Parliamentary question was asked by Andrew Gwynne on 2015-11-02.

To ask the Secretary of State for Justice, what estimate he has made of the value of stationery that has been (a) lost and (b) stolen from his Department in each of the last five fiscal years; and what the cost was of replacing such stationery.

Mr Shailesh Vara

The information requested could only be obtained at disproportionate cost.

The below Parliamentary question was asked by Andrew Gwynne on 2015-11-24.

To ask the Secretary of State for Health, what estimate he has made of the (a) forecast reduction in cases of and deaths from infection by Group C meningococcal disease as a result of the introduction of the meningitis C vaccine to the UK schedule in 1999, (b) number of meningitis C vaccinations administered in each year since that programme began and (c) cost of delivering that programme in each year since 1999.

Jane Ellison

Deaths have fallen from 110 in 1998/99 to an annual average of 3 deaths over the last 10 years. Annual MenC cases and deaths have therefore been respectively 97% and 96% lower in the last 10 years than in the year before vaccination was available.

Routine immunisation programmes with MenC containing vaccines have changed since 1999 and this has affected the ability to collect estimate annual numbers of doses administered for each vaccine offered but currently around 96% of infants receive MenC vaccine and 93% of one year olds receive their MenC-Hib booster in England by their second birthday. Coverage data are not routinely collected on the third dose in adolescence (currently MenACWY vaccine) which began in the 2013-2014 school year.

The administrative costs for the MenC programme are included in the global sum payment to general practitioners (managed by NHS England) which covers the costs of providing essential and additional primary care services.

The below Parliamentary question was asked by Andrew Gwynne on 2015-12-17.

To ask the Secretary of State for Health, if he will maintain patient access to technologies considered through commissioning through evaluation programmes during that evaluation.

George Freeman

There are two main phases for any treatments entered into NHS England’s Commissioning through Evaluation (CtE) programme.

During the first phase, an agreed number of patients are recruited to the scheme within just a few participating centres across England. This enables patients to benefit from the skills and expertise in each centre, within an evaluation programme, whilst detailed clinical and patient experience data are collected.

Once the total number of patients have been treated, the scheme enters an analysis phase. Whilst any patients already treated under the scheme will continue to receive appropriate follow up care, no new patients will be funded by NHS England during the analysis phase.

This ensures that NHS England directs the majority of public funds to evidence based care and also means that dedicated CtE programme funding can then be redirected to support patient recruitment in another area of specialised care where further evaluation data is needed.

This represents a continuation of NHS England’s published policy position for the treatment concerned (i.e. that the treatment is not routinely commissioned by the National Health Service).

The below Parliamentary question was asked by Andrew Gwynne on 2016-01-14.

To ask the Secretary of State for Work and Pensions, what projects his Department plans to fund through the £40 million allocated to the Health and Work Innovation Fund.

Priti Patel

The Work and Health innovation fund will be used to build an evidence base for what works to improve employment and health outcomes.

This evidence base will enable the Work and Health Unit to develop proposals for Longer Term reform across Work and health Systems The Unit is currently working with partners including NHS England to develop these proposals.

The below Parliamentary question was asked by Andrew Gwynne on 2016-01-27.

To ask the Secretary of State for Defence, whether his Department has an insurance policy in place for civilian residents on the land around RAF Northolt to cover possible damage to their properties.

Mark Lancaster

The Ministry of Defence does not purchase insurance policies in the UK but accepts its own risks and acts as its own insurer.

The below Parliamentary question was asked by Andrew Gwynne on 2016-01-28.

To ask the Secretary of State for Health, what the budget was for the Rare and Imported Pathogens Laboratory in each of the last five years.

Jane Ellison

Public Health England (PHE) was formed on 1 April 2013; below are budgets for the Rare and Imported Pathogens Laboratory (RIPL) for each year since PHE’s formation. The RIPL was previously part of the Health Protection Agency, whose functions transferred to PHE.

2013/14 (Actual)	2014/15 (Actual)	2015/16 (Budget)
£3,491,300	£3,667,600	£3,465,300

The below Parliamentary question was asked by Andrew Gwynne on 2016-02-02.

To ask the Secretary of State for Health, whether the Prime Minister has seen a draft childhood obesity strategy document.

Jane Ellison

As part of the development of the Childhood Obesity Strategy, the Secretary of State has regular meetings to discuss its content. The Childhood Obesity Strategy will be published shortly.

The below Parliamentary question was asked by Andrew Gwynne on 2016-02-05.

To ask the Secretary of State for Defence, how much his Department has paid out in compensation to (a) internal and (b) external claimants in each year since 2010.

Mark Lancaster

The amounts paid as a result of claims brought by internal and external claimants including claimants’ legal costs from Financial Year (FY) 2010-11 to FY2013-14 are shown below. The costs for FY 2014-15 are being finalised and will be published shortly.

Internal Claimants

The amounts paid in compensation, including claimants’ legal costs, for claims brought against the Ministry of Defence (MOD) by members and former members of HM Forces and civilian employees since 2010 are as follows:

Employers Liabilty Claims (including Service personnel and civilian staff)

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£83.9 million	£62.0 million	£69.5 million	£58.5 million

The vast majority of clinical negligence claims are brought by current or former members of HM Armed Forces but a small number will relate to their dependants treated in MOD medical facilities. The amounts paid in compensation, including claimants’ legal costs, for these claims since 2010 are as follows:

Clinical Negligence Claims

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£17.0 million	£6.7 million	£7.1 million	£5.8 million

External Claimants

Public Liability Claims

The amounts paid in compensation, including claimants’ legal costs, for public liability claims brought against the MOD by third parties, including civilians both in the UK and overseas, relating to personal injury or property damage since 2010 are as follows:

FY 2010-11	2011-12	2012-13	2013-14
£5.4 million	£10.0 million	£25.0 million	£11.1 million

Third Party Motor Claims in UK

The amounts paid in compensation, including claimants’ legal costs, for claims brought against the MOD by third parties involved in collisions with MOD-operated vehicles since 2010 are as follows:

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£5.6 million	£6.7 million	£4.8 million	£5.0 million

Area Claims Offices

The amounts paid in compensation, including claimants’ legal costs, for claims brought against the MOD by third parties that are managed by the MODs regional Area Claims Offices since 2010 are as follows:

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£3.0 million	£1.8 million	£1.7 million	£1.5 million